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Background: Reprogramming cellular gene transcription sustains HTLV-1 viral persistence that ultimately leads to
the development of adult T-cell leukemia/lymphoma (ATLL). We hypothesized that besides these quantitative
transcriptional effects, HTLV-1 qualitatively modifies the pattern of cellular gene expression.
Results: Exon expression analysis shows that patients’ untransformed and malignant HTLV-1+ CD4+ T-cells exhibit
multiple alternate exon usage (AEU) events. These affect either transcriptionally modified or unmodified genes,
culminate in ATLL, and unveil new functional pathways involved in cancer and cell cycle. Unsupervised hierarchical
clustering of array data permitted to isolate exon expression patterns of 3977 exons that discriminate uninfected,
infected, and transformed CD4+ T-cells. Furthermore, untransformed infected CD4+ clones and ATLL samples
shared 486 exon modifications distributed in 320 genes, thereby indicating a role of AEUs in HTLV-1
leukemogenesis. Exposing cells to splicing modulators revealed that Sudemycin E reduces cell viability of HTLV-1
transformed cells without affecting primary control CD4+ cells and HTLV-1 negative cell lines, suggesting that the
huge excess of AEU might provide news targets for treating ATLL.
Conclusions: Taken together, these data reveal that HTLV-1 significantly modifies the structure of cellular
transcripts and unmask new putative leukemogenic pathways and possible therapeutic targets.
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HTLV-1 causes chronic infection that relies on the
persistent clonal expansion of infected CD4+ and CD8+
T-cells. Reprogramming of gene transcription sustains
HTLV-1 viral persistence and ultimately leads to the
development of adult T-cell leukemia/lymphoma
(ATLL) from a CD4+-infected clone in a minority of
carriers after a prolonged latency [1]. Transcriptome
analyses using microarray technology has provided key
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[2-14]. HTLV-1 has been found to deregulate the expres-
sion of numerous genes involved in key cellular pathways
such as the cell cycle, apoptosis, telomeres/telomerase,
DNA repair, and immune and inflammatory responses
through expression of the Tax oncoprotein [2-6].
Recent works have highlighted that in addition to
their quantitative effects on gene expression, numerous
pathogenic processes, such as persistent viral infections
[15] or tumor development [16,17], rely on acquired
alternate exon usage (AEU) events. As for other retrovi-
ruses, alternative splicing plays a pivotal role in HTLV-1
expression. From its 5’LTR, HTLV-1 transcribes a single
polycistronic pre-mRNA that codes for structural and
enzymatic proteins required for viral particle production.
This pre-mRNA also undergoes multiple alternative spli-
cing events that generate mono-spliced transcripts coding. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Thénoz et al. Retrovirology  (2014) 11:119 Page 2 of 9for the regulatory proteins p21Rex, p12 and p13, and
double-spliced transcripts coding for Tax, p27Rex and p30
[18,19]. Similarly, minus-strand transcription initiated from
the 3’LTR generates spliced and unspliced RNA isoforms of
HBZ that synthesize HBZ proteins with distinct properties
on cell proliferation [20-22]. How HTLV-1 intervenes in al-
ternative splicing processes is still incompletely understood.
It has been reported that the RNA-binding protein Rex
regulates viral splicing through interacting with host spli-
cing machinery to inhibit viral RNA splicing and export
unspliced and single-spliced transcripts [23-25]. Gene-
by-gene analyses have further shown that HTLV-1 may
affect alternative splicing of cellular genes including CD44
[26] and IL-6- and IL-2-receptors [27,28], proposing that
HTLV-1-induced AEUs might contribute to molecular
mechanisms that underlie the clonal expansion and the ma-
lignant transformation of infected cells. However, no sys-
tematic study has been hitherto conducted to ascertain the
extent of alternative splicing modifications upon HTLV-1
infection. Here, by using integrative analysis of exon expres-
sion profiles and gene ontology of CD4+ T-cells derived
from infected individuals with and without malignancy, we
show that HTLV-1 induces multiple AEU alterations that
unmask new putative leukemogenic pathways and possible
therapeutic targets.
Results and discussion
Comparative microarray analysis of exon expression pro-
files was performed with three ATLL samples and 12
untransformed CD4+ T-cell clones (six infected) derived
from HTLV-1-infected individuals with no clinical signs of
malignancy. ATLL samples were obtained from patients
with an acute form of ATLL (>95% circulating malignant
cells). CD4+ clones were obtained through cloning by limit-
ing dilution of peripheral blood mononuclear cells (PBMCs)
derived from three HTLV-1-infected individuals with trop-
ical spastic paraparesis/HTLV-1-associated myelopathy with
a disease duration of 6, 11, and >26 years. This study was
conducted according to the principles outlined in the Dec-
laration of Helsinki, and approved by the Institutional Re-
view Board of the Hospices Civils de Lyon (France). As
previously described [29,30], CD4+ clones were submitted to
ex vivo culture for one month prior to HTLV-1 screening
and RNA extraction. At this time, infected and uninfected
cells remained non-immortalized and required IL-2 for con-
tinued growth. Given that in vitro T-cell activation is known
to modify AEU [31,32], exon array analysis of untrans-
formed CD4+ clones was carried out with RNAs extracted
from unstimulated and phytohemagglutinin (PHA)-stimu-
lated CD4+ T-cells (Additional file 1: Table S1). By this
approach that take into account the in vitro cell culture, we
assumed that significant changes in exon expression be-
tween infected and uninfected clones mainly resulted
from the global impact of HTLV-1 infection, irrespectiveof activation status. The microarray data have been depos-
ited in toto into the Gene Expression Omnibus database
and are available under record number GSE52244.
HTLV-1 expression was assessed by quantitative RT-PCR
(qRT-PCR) of Tax transcripts. In accordance with previous
reports, Tax transcripts were weakly detected in 2 out of 3
ATLL samples (Additional file 2: Figure S1) [33-35]. In
comparison, there was a wide range of Tax expression
between clones (0.16-2.20; median, 1.2; mean ± standard
deviation [SD], 1.172 ± 0.799). From these data, we as-
sumed that HTLV-1 samples exhibited typical features of
untransformed- and transformed-infected CD4+ T-cells
in vivo. Computational analyses of 15 exon arrays and
annotation of exon events were achieved as detailed in
Figure 1. Figure 1A represents the distribution of quantita-
tive and qualitative gene modifications in untransformed
HTLV-1-infected CD4+ clones and ATLL cells. A total of
18/20 (90%) array-predicted exon usages were validated by
exon-specific RT-PCR (Figures 1C and D). Among those,
we found alternative splicing changes in IL2-R and CD44
transcripts (Figure 1C). These data confirmed and extended
previous observations indicating that IL2-R and CD44 vari-
ant isoforms are detected in the PBMC of infected individ-
uals [26,28]. Array-predicted changes in transcript
abundance were validated by qRT-PCR for 8/9 (88%) genes
(Additional file 3: Figure S2).
To examine the global impact of HTLV-1 on AEU of
CD4+ T-cells, we investigated AEU in untransformed
CD4+ T-cells by comparing the pattern of exon expres-
sion in infected versus uninfected clones (Figure 1A;
Additional file 1: Table S1). Overall, 2201 AEU events
were identified in 1271 genes, of which only 656 (51%)
were found altered at the level of whole gene expression.
This demonstrated that in untransformed cells, HTLV-1
significantly modifies the exon content of multiple tran-
scripts, considering half of these genes were transcrip-
tionally unmodified. Secondly, when ATLL samples were
compared with uninfected clones, the overall number
of AEU events was found to be 11-fold (23504 versus
2201) higher than that distinguishing HTLV-1-positive
from -negative untransformed CD4+ T-cells (Figure 1A).
In addition to this quantitative difference, the proportion
of AEU events found in differentially expressed genes was
significantly higher in ATLL samples (72% versus 51% in
uninfected clones; p < 0.0001, Pearson’s Chi-squared test;
Figure 1A). Together these results indicate that the dis-
tribution of AEU alterations was significantly different
between ATLL and HTLV-1-positive untransformed cells.
The comparative analysis of AEU between the two cat-
egories of infected cells revealed that infected CD4+
clones and ATLL samples shared 486 AEUs in 329 genes
(p = 1.83 × 10−21, Hypergeometric test), suggesting that
22% of AEUs arising at the chronic stage of infection
might pertain to ATLL development. The number of AEUs
Figure 1 Distribution of AEU in ATLL cells and cloned CD4+ T-cells derived from HTLV-1-infected individuals. (A) Distribution of quantitative
and qualitative HTLV-1 modifications in untransformed HTLV-1-positive CD4+ clones and ATLL samples. The Venn-diagrams show the distribution of genes
modified at the whole gene expression level (white), AEU (dark grey), or both (light grey) in ATLL samples (bottom) and untransformed infected clones
(top; six independent data sets including three PHA-activated and three unactivated clones) versus uninfected clones (six independent data
sets including three PHA-activated and three unactivated clones). Graphs present the distribution of each class of AEU annotated according to
the FASTERDB database [41]. Acceptor: alternative acceptor site; deletion: exon deletion; donor: alternative donor site; exon: exon skipping;
intron-ret: intron retention; polya: alternative polyadenylation site; prom: alternative promoter. The total number of each class of exon event is
indicated on the histogram bar. (B) GO analysis of genes (n = 329) presenting common AEUs in untransformed-infected clones and in ATLL samples
(compared with uninfected clones). The complete set of genes featured in microarrays (42304 Ensembl geneIDs) was used as a reference background.
Gene annotations are presented in Additional file 5: Table S3. (C) RT-PCR validation of microarray-predicted exon events in CD4+ T-cells derived
from HTLV-1 carriers compared with uninfected T-cell clones. Exon-specific RT-PCR was performed with pooled RNA samples derived from six infected
(I) and six uninfected (UI) clones, thereby reflecting the distribution of splice variants in all clones irrespective of activation status. Numbers indicate the
expected band (bp) of PCR products, and the SI and p-value are indicated for each exon event; a SI≥ 1.2 was considered to be a significant change in
exon expression and used for comparisons. (D) RT-PCR validation of microarray-predicted exon events in ATLL cells (array) and exon-specific RT-PCR of six
additional ATLL samples compared to uninfected T-cell clones.
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1.47 ± 1.42; Additional file 4: Table S2). GO enrichment
analysis (DAVID resources, http://david.abcc.ncifcrf.gov/)
performed with this set of genes identified several enriched
terms that fit well with HTLV-1 infection and relateddiseases, such as pathways in cancer (fold enrichment
[FE]: 2.71), endocytosis (FE: 4.45), antigen processing
and presentation (FE: 7.23), cell adhesion molecules
(CAMs; FE: 4.56), and natural killer cell-mediated cyto-
toxicity (FE: 4.46; Figure 1B; Additional file 5: Table S3).
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that alternative expression of 3977 exons (2218 genes)
permitted sample gathering in three distinct clusters,
including untransformed-uninfected and infected CD4+
clones, as well as ATLL samples (p < 0.05, Kruskal-Wallis
ANOVA; Figure 2A). For untransformed cells, these exon
expression profiles were irrespective of PHA stimulation,
implying a direct role of HTLV-1 in these recurrent
alternative splicing modifications. ATLL cells exhibited
marked changes in AEU compared to untransformed
HTLV-1-positive or -negative CD4+ clones. Such distri-
bution suggests that some AEU events could represent
an ATLL molecular signature. Therefore, we used exon-
specific RT-PCR to analyze six additional samples har-
vested from patients with acute forms of ATLL. Over
the 11 events identified in Figure 1D, the expression of
4 AEUs was found to be recurrent in ATLL (Figure 1D).
Whether the AEUs shown in Figures 1B, D, and 2A areFigure 2 Exon-based hierarchical clustering. Hierarchical clustering anal
the gene-normalized exon intensities. (A) The selection of exons useful for
using a Kruskal-Wallis ANOVA with p < 0.05 representing statistical signifi
corresponded to 2000 genes that displayed the highest splicing index (S
Ensembl geneIDs) was used as a reference background. Official gene syminvolved in ATLL development and possess diagnostic and/
or prognostic implications deserves further investigation.
A GO analysis was performed to gain insight into the
functional significance of the exon expression profiles
(3977 exons) that discriminate between the three groups
of samples presented in Figure 2A. Significant enrich-
ment was detected for genes involved in important
biological processes, such as those related to cancer
(50 genes, FE = 1.9; p = 6.6 × 10−6), MAPK signaling
(46 genes, FE: 2.2; p = 6.1 × 10−7), focal adhesion (34
genes, FE: 2.2; p = 5.5 × 10−5), cytokine-cytokine re-
ceptor interactions (34 genes, FE: 1.7; p = 0.003),
and endocytosis (32 genes, FE: 2.2; p = 3.2 × 10−5;
Figure 2B). Official symbol annotation of genes with
AEUs that are enriched in these pathways are pre-
sented in (Additional file 6: Table S4). Secondly, GO
analysis of AEU events detected in ATLL samples
(7616 genes) and untransformed HTLV-1-positive CD4+ysis was performed with Mev4.0 software (http://www.tm4.org/) using
differentiating between the 15 cell samples was statistically analyzed
cance. (B) GO analysis. Top pathways are presented. The gene set
I) values. The complete set of genes featured in microarrays (42304
bol annotations are presented in Additional file 5: Table S3.
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changes (Additional file 7: Figure S3). For example,
genes encoding spliceosome components appeared
exclusively enriched in ATLL cells, while cell cycle-
related genes were found enriched in untransformed
and transformed HTLV-1 positive samples. Moreover,
AEU ontological enrichments were different from those of
differentially expressed genes (Additional file 7: Figure S3).
Together, these results suggest that HTLV-1-related
transcriptional and post-transcriptional changes might
pose distinct functional impacts on untransformed and
malignant cells.
The plethora of splicing events found in transformed
and untransformed-infected cells suggests that spliceo-
some components might constitute new therapeutic
targets in the management of HTLV-1 infection. Thus,
we examined whether the spliceosome modulators
Sudemycin E and D1 [36] exerted anti-proliferative
activity against HTLV-1 T-cell lines. To this end, cell
viability upon drug exposure was compared between
HTLV-1-transformed cell lines (MT2 and HUT-102)
and uninfected cells, including primary CD4+ T-cells and
the HTLV-1-negative acute lymphoblastic leukemia
cell line, MOLT4. Figure 3A shows that increasing the
concentration of Sudemycin D1 led to a rapid decrease
in the viability of human cell lines whether they carried
HTLV-1 proviruses or not, while growth of primary
CD4+ T-cells was inhibited at higher drug concentra-
tions. In contrast, a similar Sudemycin E concentration
range was found to significantly decrease the viability
of HTLV-1 cell lines, while displaying weak effects on
primary CD4+ and MOLT4 cells. High concentration of
Sudemycin E (>5 μM) affected cell viability of all tested
cells, carrying or not HTLV-1 (not shown). These
data suggest that, compared to both transformed and
untransformed-uninfected cells, HTLV-1 tumoral cells
are highly sensitive to drugs that target splicing ma-
chinery. Time-course analysis confirmed these results
and further revealed that the anti-proliferative effect
of Sudemycin E was persistent in MT2 and HUT-102
HTLV-1-positive cells relative to HTLV-1-negative
CD4+ and MOLT4 cells (Figure 3B).
Further analyses examined the impact of Sudemycin E
on the expression of viral and cellular genes. Figure 3C
shows that Sudemycin E dose-dependently induced the
expression of short spliceoforms of MDM2 and caspases
2 and 9 that have been previously correlated with apop-
tosis induction [37,38]. In contrast, the expression of
ubiquitin, resulting from constitutive splicing of intron
3, remained unaffected. This indicates that Sudemycin E
only affected alternative splicing, rather than whole gene
transcription, of apoptotic regulatory genes. In parallel,
as Tax is synthetized by double-spliced viral transcripts,
we examined whether Sudemycin E could affect Taxprotein levels. As shown in Figure 3D, western blot
analysis of MT2 and HuT102 cell lines revealed that
increasing the concentration of Sudemycin E led to
reduced Tax expression. Because ATLL cells barely
express Tax but regularly show high levels of HBZ
mRNA, we next aimed at testing the effects of Sudemy-
cin E on HBZ expression. In contrast to Tax, HBZ
expression is not strictly dependent on splicing events.
In fact, HTLV-1 minus strand encodes spliced (sHBZ)
and unspliced isoforms (unHBZ) of HBZ, yet sHBZ is
the most abundant in HTLV-1 transformed cell lines
and in fresh ATLL samples [20,39]. In contrast to its
unspliced counterpart, sHBZ promotes cell proliferation
in vitro thereby likely explaining the positive correlation
between sHBZ expression and HTLV-1 proviral loads
in vivo [21,39]. These data prompted us to assess the ex-
pression levels of both sHBZ and usHBZ RNA isoforms
in Sudemycin E exposed cells using exon-specific quan-
titative RT-PCR analysis. The results illustrated in the
Figure 3E show that both MT2 and HUT102 cells
exhibited reduced ratios of sHBZ/unHBZ upon Sude-
mycin E together with a dramatic decrease in the overall
level of unHBZ expression, which is consistent with the
transactivating functions of sHBZ on HBZ gene expres-
sion [40]. Given the crucial role of both Tax and sHBZ
in conferring proliferative and anti-apoptotic properties,
these data help explain the heightened sensitivity of
HTLV-1-infected cells to the anti-proliferative properties
of Sudemycin E compared to their uninfected counter-
parts. Taken together, our results indicate that by impair-
ing splicing and, in turn, gene expression of HTLV-1
oncogenes, splicing modulators such as Sudemycin E
might constitute promising tools for ATLL treatment.
Conclusions
Our investigation revealed that HTLV-1 significantly
qualitatively modifies gene transcripts, as well as un-
masks new putative leukemogenic pathways and pos-
sible therapeutic targets. Because alternative splicing
can result in mRNA isoforms coding for proteins with
different biological activity, our results suggest that
excessive splicing alterations in HTLV-1-positive cells
might underlie their phenotypic plasticity. Future studies
are needed to address the molecular mechanisms under-
lying HTLV-1-induced AEU and their involvement in
clonal persistence, immune escape, and/or cellular trans-
formation of infected CD4+ cells, as well as their putative
role in treatment resistance and relapse of ATLL.
Methods
T cell limiting cloning
Peripheral blood mononuclear cells (PBMCs) were ob-
tained by Ficoll separation of whole blood of HTLV-1 in-
fected individuals. For T-cell limiting dilution cloning,
Figure 3 Anti-proliferative effect of Sudemycin E on HTLV-1-transformed cell lines. (A) Cell viability was determined by MTT assay (Cell Titer 96®
Non-Radioactive Cell Proliferation Assay, Promega) 72 h after Sudemycin (D1 or E) exposure. Data represent normalized mean ± SD; *p < 0.05 was
considered statistically significant using a Mann–Whitney U-test. (B) Time-course analysis over 96 h using 1 μM of Sudemycin. Experiments were
performed twice, in triplicate for each cell type, with DMSO used as control. Data represent the normalized mean ± SD. (C) Sudemycin E-induced
expression of short spliceoforms encoding caspases 2 and 9 and MDM2. Exon-specific RT-PCR was carried out 72 h after Sudemycin E exposure.
The oligonucleotides used have been previously described [36]. (D) Sudemycin E reduces Tax expression. Western blot analysis of Tax expression
was carried out with a mouse monoclonal anti-Tax antibody (clone 474) 72 h after Sudemycin E exposure. Histograms represent the quantification of
Tax signals normalized against beta-actin. (E) Sudemycin E decreases gene expression level of HBZ and the relative ratio sHBZ/unHBZ. Isoform-specific
qRT-PCR analysis was carried out after 72 h of Sudemycin exposure. HBZ isoform expressions were normalized to hprt-1 transcripts used as
internal control.
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after removal of adherent cells. T-lymphocytes were
cultured in RPMI 1640 containing penicillin and strep-
tomycin, sodium pyruvate, non-essential amino acids,
2-mercaptoethanol, 10% filtered human AB serum,
100 U/mL recombinant IL-2 (Chiron Corporation), and
75 μM HTLV-1 integrase inhibitor L-731,988 [30]. T-
lymphocytes were re-stimulated every 14 days with
PHA (1 μg/mL) and fresh feeder cells (5.105 cells/mL)
that were composed of lethally irradiated PBMCs from
three distinct allogenic HTLV-1-negative donors. Clones
were phenotyped by flow cytometry using antibodies
against CD4 and CD8 (DakoCytomation) and isotype-
matched controls on a FACScan system using CellQuest
software (Becton Dickinson). HTLV-1-positive clones
were assessed by PCR using long-terminal repeat re-
gion–specific primers as previously described [29]. For
each clone, RNA extraction was performed before and
24 h after PHA stimulation.
Microarray analysis
Affymetrix exon array hybridization was completed by
labeling 1 μg of TRIzol-purified total RNA with Affyme-
trix reagents according to the manufacturer’s instructions.
Hybridization cocktails containing 5–5.5 μg cDNA were
prepared and hybridized to Affymetrix-GeneChip Human
Exon 1.0 ST arrays (Affymetrix). Affymetrix Expression
Console Software was used for quality assessment,
while exon array data were normalized using quintile
normalization and analyzed using FasterDB annotation
(https://fasterdb.lyon.unicancer.fr/) [41]. Background
correction and probe selection were performed as de-
scribed previously [42]. Statistical analyses were performed
using a Student’s t-test on the splicing index (SI) that
corresponds to comparison of gene-normalized exon
intensity values between two experimental conditions
[30,42]. According to exon-specific RT-PCR (Figures 1C
and D), microarray data were considered statistically
significant for p < 0.05 and SI ≥ 1.2.
Polymerase chain reaction
PCR was performed using the Herculase II Fusion DNA
Polymerase (Agilent Technologies) in 30–35 cycles. PCR
products were analyzed by agarose gel electrophoresis
with ethidium bromide under UV light. Primers were
designed to encompass alternative splicing events.
Primer sequences are available upon request.
Quantitative RT-PCR
Expression of Tax mRNA was quantified with Rotor Gene
(Qiagen) as previously described [29,43]. Expression of
sHBZ and unHBZ was quantified using primers previ-
ously described by Murata et al. [44]. qRT-PCR was per-
formed in triplicate and relative quantitation (RQ) wascalculated by the 2ddCT method to normalize gene expres-
sion to the endogenous control U6 (ENSG00000206625) or
hprt1 (ENSG00000165704).
Drug exposure and cell viability
Cell viability was determined by MTT assay (Cell Titer
96® Non-Radioactive Cell Proliferation Assay, Promega)
72 h after Sudemycin (D1 or E) exposure. The MTT dye
was added during the last hour of incubation. After,
supernatants were removed and cells were incubated
with 100 μL/well Solubilization Solution/Stop Mix for
1 h at room temperature. The OD was measured using
an ELISA reader at 570 nm, with 650 nm as a reference.
Experiments were completed twice, in triplicate for each
cell type, with DMSO used as control.
Additional files
Additional file 1: Table S1. List of samples.
Additional file 2: Figure S1. Tax expression in infected clones and ATLL
samples. Tax mRNA was quantified by real-time qRT-PCR as described
previously [29,43]. *Statistically significant differences by Mann–Whitney
U-test.
Additional file 3: Figure S2. qRT-PCR confirmation of overall gene
expression. cDNA was amplified by qRT-PCR in 20 μl reactions using a
QuantiFast SYBR Green PCR Kit (Qiagen) with 10 μM of each primer.
Reactions were run on a Rotor-Gene 3000 (Corbett Life Science, Australia).
HRPT1 gene expression was used as an internal control. A melting curve
(57–95°C) was generated at the end of each run to verify primer specificity.
The Pfaffl method was used for relative quantification. Primer sequences
are available upon request. FC, indicates microarray-predicted positive or
negative fold-changes in gene expression between infected and uninfected
CD4+ cells; CD4UI, uninfected CD4+ clones; CD4I, infected CD4+ clones.
Additional file 4: Table S2. Common AEUs between untransformed-
infected CD4+ clones and ATLL samples (compared with uninfected
clones).
Additional file 5: Table S3. GO terms enriched by genes with common
AEUs in untransformed-infected clones and ATLL samples (compared
with uninfected clones).
Additional file 6: Table S4. GO terms enriched by genes displaying
AEUs that discriminate between uninfected and infected clones and ATLL
samples.
Additional file 7: Figure S3. GO analysis in ATLL samples and
untransformed clones according to whole gene expression and AEU. The
Venn-diagrams show the distribution of genes modified at the whole
gene expression level (white; FC ≥ 1.2; p < 0.05), AEU level (dark grey; SI≥
1.2; p < 0.05), or both (light grey). Each gene set was analyzed using the
DAVID browser (http://david.abcc.ncifcrf.gov/; KEGG pathways). Each gene
set was limited to 2000 genes that displayed the highest fold-change in
expression and splicing index (SI) values. The complete set of genes
featured in microarrays was used as reference background. Top pathways
are presented.
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